share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Return

Hong Kong Stock Exchange ·  May 13 22:41
Summary by Futu AI
药明生物（WuXi Biologics (Cayman) Inc.）於2024年5月13日提交了翌日披露報表，披露了自2023年12月7日至2024年5月13日期間的股份購回活動。該公司在此期間進行了多次股份購回，但並未註銷這些股份。最後一次購回發生在2024年5月13日，當日購回2,261,000股，每股價格介於HKD 13.9至HKD 14.54之間，總計花費約HKD 31,967,150。自普通決議案通過以來，公司在香港聯合交易所總共購回了100,243,000股，佔已發行股份的2.35954%。药明生物確認，所有購回活動均符合《主板上市規則》/《GEM上市規則》的規定。
药明生物（WuXi Biologics (Cayman) Inc.）於2024年5月13日提交了翌日披露報表，披露了自2023年12月7日至2024年5月13日期間的股份購回活動。該公司在此期間進行了多次股份購回，但並未註銷這些股份。最後一次購回發生在2024年5月13日，當日購回2,261,000股，每股價格介於HKD 13.9至HKD 14.54之間，總計花費約HKD 31,967,150。自普通決議案通過以來，公司在香港聯合交易所總共購回了100,243,000股，佔已發行股份的2.35954%。药明生物確認，所有購回活動均符合《主板上市規則》/《GEM上市規則》的規定。
WuXi Biologics (Cayman) Inc., filed a Next Day Disclosure Report on May 13, 2024, disclosing share repurchase activities for the period December 7, 2023 to May 13, 2024. The company has made several share repurchases during this period, but has not written them off. The last repurchase took place on May 13, 2024, and repurchased 2,261,000 shares at a price of HKD 13.9 to HKD 14.54 for a total cost of approximately HKD 31,967,150. Since the adoption of the Ordinary Resolution, the company has repurchased a total of 100,243,000 shares on the Hong Kong Stock Exchange, representing 2.35954% of the issued shares. Pharma Bio confirms that all repurchases comply with the provisions of the Main Board Listing Rules/GEM Listing Rules.
WuXi Biologics (Cayman) Inc., filed a Next Day Disclosure Report on May 13, 2024, disclosing share repurchase activities for the period December 7, 2023 to May 13, 2024. The company has made several share repurchases during this period, but has not written them off. The last repurchase took place on May 13, 2024, and repurchased 2,261,000 shares at a price of HKD 13.9 to HKD 14.54 for a total cost of approximately HKD 31,967,150. Since the adoption of the Ordinary Resolution, the company has repurchased a total of 100,243,000 shares on the Hong Kong Stock Exchange, representing 2.35954% of the issued shares. Pharma Bio confirms that all repurchases comply with the provisions of the Main Board Listing Rules/GEM Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.